Finally, current evidence provides support for the feasibility of novel therapeutic targets, such as Klotho, VD/VDR, and rapamycin, but information regarding the mechanism of action of these compounds will be necessary for expanding the spectrum of DKD treatment. This evidence concerns the gene KL and diabetic kidney disease.